- Home
- SVRA vs PHAT Comparison
SVRA vs PHAT Comparison
Compare SVRA & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SVRA
- PHAT
- Stock Information
- Founded
- SVRA N/A
- PHAT 2018
- Country
- SVRA United States
- PHAT United States
- Employees
- SVRA N/A
- PHAT N/A
- Industry
- SVRA Biotechnology: Pharmaceutical Preparations
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- SVRA Health Care
- PHAT Health Care
- Exchange
- SVRA Nasdaq
- PHAT Nasdaq
- Market Cap
- SVRA 540.6M
- PHAT 465.0M
- IPO Year
- SVRA N/A
- PHAT 2019
- Fundamental
- Price
- SVRA $2.80
- PHAT $6.79
- Analyst Decision
- SVRA Buy
- PHAT Strong Buy
- Analyst Count
- SVRA 7
- PHAT 4
- Target Price
- SVRA $9.86
- PHAT $23.00
- AVG Volume (30 Days)
- SVRA 966.0K
- PHAT 975.7K
- Earning Date
- SVRA 03-06-2025
- PHAT 03-06-2025
- Dividend Yield
- SVRA N/A
- PHAT N/A
- EPS Growth
- SVRA N/A
- PHAT N/A
- EPS
- SVRA N/A
- PHAT N/A
- Revenue
- SVRA N/A
- PHAT $26,270,000.00
- Revenue This Year
- SVRA N/A
- PHAT $7,622.43
- Revenue Next Year
- SVRA N/A
- PHAT $239.05
- P/E Ratio
- SVRA N/A
- PHAT N/A
- Revenue Growth
- SVRA N/A
- PHAT N/A
- 52 Week Low
- SVRA $2.60
- PHAT $6.07
- 52 Week High
- SVRA $5.70
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- SVRA 39.71
- PHAT 35.37
- Support Level
- SVRA $2.60
- PHAT $6.36
- Resistance Level
- SVRA $3.14
- PHAT $7.20
- Average True Range (ATR)
- SVRA 0.17
- PHAT 0.50
- MACD
- SVRA -0.01
- PHAT 0.08
- Stochastic Oscillator
- SVRA 32.79
- PHAT 22.11
About SVRA Savara Inc.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.